Product category:
Clinical chemistry analysis
News Release from: Lab21 | Subject: Ox-LDL diagnostic
Edited by the Laboratorytalk Editorial
Team on 12 October 2007
Predictive diagnostic for coronary heart
disease
The oxidised low density lipoprotein (oxLDL) diagnostic test is expected to radically alter the clinical diagnosis of heart attacks in the emergency room setting
Lab 21 has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidised low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart disease (CHD) The oxLDL test can identify those individuals at the greatest risk of developing CHD, allowing for early preventative action
This article was originally published on Laboratorytalk on 26 Jul 2005 at 8.00am (UK)
Related stories
Antiviral drug discovery and clinical trials
Array of spearhead tests and services available include lead identification and optimisation, resistance profiling, clinical candidate selection and selectivity evaluation in pre-clinical situations
Liver disease assessment service is 'breakthrough'
System substitutes for biopsy by using surrogate markers of liver disease that can be measured using simple blood tests
Ox-LDL is released from atherosclerotic plaque in increasing amounts as the plaque becomes more unstable, and thus with the increasing likelihood that an area of it will break away from the surface of the blood vessel and obstruct either the coronary artery (causing a heart attack) or a cerebral vessel (causing a stroke).
Because oxLDL has a very short half life within the blood, measuring it accurately is difficult.
However, the body rapidly produces auto-antibodies and these can be measured by the appropriate antigens.
Berwyn Clarke, CSO of Lab21, commented: "Heart attacks due to atherosclerosis are the greatest cause of mortality in the developing world and we are very pleased to licence this diagnostic to such a globally important health issue.
"We hope this test will enable the more accurate definition of certain forms of cardiac disease helping reduce the incidence of heart attacks and providing obvious economic benefit to healthcare providers worldwide".
The oxLDL antibody assay is CE marked and is an Elisa test based upon a novel diagnostic approach with intellectual property surrounding the peptide antigens used.
It will be manufactured by Newmarket Laboratories which is part of the Lab21 group of companies.
Christian Goodwin, head of immunodiagnostics at Newmarket Laboratories, explains: "The determination of antibodies to oxLDL as opposed to the measurement of oxLDL directly is important since oxLDL has a short half life and is unstable; antibody determination is a much more reliable technique to determine an individual's exposure and risk profile to this atherogenic factor.
"Early clinical studies have already shown that the test performs favourably against all current gold standard diagnostic markers.".
• Lab21: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
